International Cancer Conference Journal最新文献_第5页

Neuroendocrine tumor of the minor duodenal papilla with lymph node metastasis: a case report and literature review. 十二指肠小乳头神经内分泌肿瘤伴淋巴结转移：一例报告和文献复习。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-07-30 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00624-8

Hideo Ota, Shigekazu Yokoyama, Kazunori Yanagawa, Sadaharu Iio, Mutsumi Fukunaga

{"title":"Neuroendocrine tumor of the minor duodenal papilla with lymph node metastasis: a case report and literature review.","authors":"Hideo Ota, Shigekazu Yokoyama, Kazunori Yanagawa, Sadaharu Iio, Mutsumi Fukunaga","doi":"10.1007/s13691-023-00624-8","DOIUrl":"10.1007/s13691-023-00624-8","url":null,"abstract":"Whether pancreatoduodenectomy or papillary resection should be performed to achieve curative treatment for neuroendocrine tumors of the minor duodenal papilla with a diameter of ≤2 cm is controversial. We report a 35-year-old male patient with a rare case of a neuroendocrine tumor of the minor duodenal papilla. The patient was referred to our hospital from a different clinic for dilatation of his minor duodenal papilla. Duodenoscopy revealed a smooth mass of 2 cm in diameter in the minor papilla, and the biopsy specimen was diagnosed as neuroendocrine tumor G1. The patient underwent subtotal stomach-preserving pancreatoduodenectomy. Histological evaluation showed a single nodule of 15 mm in diameter in the mucosa with metastasis to the regional lymph node. The tumor cells exhibited immunoactivity against synaptophysin and chromogranin A. The molecular immunology Borstel-1 index was less than 1%, and the grade was neuroendocrine tumor G1. We reviewed the characteristics of 24 cases of patients who underwent PD for NETs of the minor duodenal papilla in English literature. In 22 of these cases, the tumor depth was described. Lymph node metastasis was observed in none of the three cases (0%) in which the tumor was limited to the intra-sphincter; however, it was noted in three (30%) of the 10 cases in which the tumor had invaded the duodenal submucosa and in eight (89%) of the nine cases in which the tumor had invaded the muscularis propria, pancreas, peripancreatic/periduodenal tissues, or duodenal serosa. Making a definitive diagnosis preoperatively or intraoperatively whether the tumor invades beyond the sphincter or not and whether regional lymph node metastasis is present may not be possible. Therefore, we believe that pancreatoduodenectomy with lymphadenectomy is preferable for curative treatment of neuroendocrine tumors of the minor duodenal papilla.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"255-262"},"PeriodicalIF":0.5,"publicationDate":"2023-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10002504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report. pembrolizumab免疫治疗林奇综合征引起的远端十二指肠腺癌后的病理学完全反应：一例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-07-26 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00622-w

Shinichiro Ikeda, Qingjiang Hu, Keita Natsugoe, Tomoya Harima, Yasushi Tanaka, Izumi Kinoshita, Kentaro Nonaka, Sho Nambara, Ryota Nakanishi, Tomonori Nakanoko, Mitsuhiko Ota, Yasue Kimura, Eiji Oki, Yoshinao Oda, Tomoharu Yoshizumi

{"title":"A pathological complete response after immunotherapy with pembrolizumab for distal duodenal adenocarcinoma caused by Lynch syndrome: a case report.","authors":"Shinichiro Ikeda, Qingjiang Hu, Keita Natsugoe, Tomoya Harima, Yasushi Tanaka, Izumi Kinoshita, Kentaro Nonaka, Sho Nambara, Ryota Nakanishi, Tomonori Nakanoko, Mitsuhiko Ota, Yasue Kimura, Eiji Oki, Yoshinao Oda, Tomoharu Yoshizumi","doi":"10.1007/s13691-023-00622-w","DOIUrl":"10.1007/s13691-023-00622-w","url":null,"abstract":"Primary adenocarcinoma of the duodenum is a rare neoplasm that is often microsatellite instability-high (MSI-H). Pembrolizumab, a monoclonal antibody, has been recently approved in Japan for treatment of MSI-H solid tumors. Lynch syndrome is a frequent hereditary cancer predisposition syndrome. It is linked to an increased risk of various types of cancer, including colorectal and endometrial cancer, and is closely related to MSI-H. We present the case of a 55-year-old woman who was diagnosed with duodenal cancer. Biopsy findings revealed MSI-H, and pembrolizumab therapy was initiated because the tumor was in contact with the left renal vein and had metastasized to the mesenteric lymph nodes of the small intestine. Subsequently, after completing two courses of pembrolizumab therapy, the patient developed duodenal stenosis and underwent surgery. Pathological analysis of the resected specimen revealed no evidence of malignancy. Given the patient's previous cancer history and the occurrence of cancer in close relatives, genetic testing of peripheral blood was performed, which revealed the diagnosis of Lynch syndrome. Furthermore, the variant responsible for Lynch syndrome was found to be a mutation of NM_000251.3:c.211 + 1G > C in MSH2.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"279-284"},"PeriodicalIF":0.5,"publicationDate":"2023-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421800/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac tamponade during pembrolizumab treatment in a patient with ovarian cancer: a case report. 一例卵巢癌症患者pembrolizumab治疗期间心脏压塞：病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-07-05 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00621-x

Wei-Ting Sung, Kunihiro Sakai, Haruka Etou, Rikiko Yamamichi, Tomoko Yoneda, Toshiaki Matsuura, Tomoyoshi Maruyama, Daisuke Nishi

引用次数: 0

A rare case of pseudomyxoma peritonei with Morgagni hernia. 一例罕见的腹膜假性粘液瘤合并Morgagni疝。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-07-05 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00614-w

Toru Imagami, Yasumitsu Oe, Byonggu An, Nobuyuki Takao, Takeshi Togawa, Akiyoshi Mizumoto

引用次数: 0

Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia. FGFR2融合基因阳性的肝内胆管癌对培咪嗪尼有反应并引起低磷血症。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-07-03 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00619-5

Yoshinori Kikuchi, Kazuhisa Yamaguchi, Ryo Shimizu, Yuu Matsumoto, Yasuko Kurose, Naoki Okano, Yuichirou Otsuka, Kazutoshi Shibuya, Takahisa Matsuda, Hideaki Shimada

引用次数: 0

Abscopal effect of radiation in metastatic esophageal carcinoma: fourth reported case. 放疗在转移性食管癌中的作用:第4例报告。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-07-01 DOI: 10.1007/s13691-023-00605-x

Rituparna Biswas, Rajesh Jindel, Anirban Halder, Koushik Sen, Apurba Kabasi

引用次数: 1

Correction to: COVID arm that appeared in the contralateral upper extremity after mRNA‑1273 booster inoculation. 修正:mRNA - 1273加强接种后对侧上肢出现的COVID臂。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-07-01 DOI: 10.1007/s13691-023-00600-2

Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Kan Yonemori

引用次数: 0

COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation. mRNA-1273加强接种后对侧上肢出现的COVID臂。

IF 0.7

International Cancer Conference Journal Pub Date : 2023-07-01 DOI: 10.1007/s13691-023-00598-7

Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Kan Yonemori

引用次数: 0

Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review. 恩特替尼诱导的Brugada综合征引起的致命性室性心律失常：一例病例报告和文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-06-26 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00620-y

Keisuke Futamura, Tetsunari Hase, Akihito Tanaka, Yoshinori Sakai, Shotaro Okachi, Hirofumi Shibata, Futoshi Ushijima, Takahiko Hashimoto, Kuniya Nakashima, Katsuki Ito, Takanori Yamamoto, Atsushi Numaguchi, Yasuya Inden, Makoto Ishii

{"title":"Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review.","authors":"Keisuke Futamura, Tetsunari Hase, Akihito Tanaka, Yoshinori Sakai, Shotaro Okachi, Hirofumi Shibata, Futoshi Ushijima, Takahiko Hashimoto, Kuniya Nakashima, Katsuki Ito, Takanori Yamamoto, Atsushi Numaguchi, Yasuya Inden, Makoto Ishii","doi":"10.1007/s13691-023-00620-y","DOIUrl":"10.1007/s13691-023-00620-y","url":null,"abstract":"Entrectinib, a multikinase inhibitor of ROS1 and tropomyosin receptor kinases, is recommended to treat ROS1-positive metastatic non-small cell lung cancer (NSCLC). In a previous study, entrectinib-related cardiotoxicity occurred in 2% of patients; however, lethal arrhythmias remain understudied. We encountered a case of fatal arrhythmia due to drug-induced Brugada syndrome caused by entrectinib. An 81-year-old Japanese male with lung adenocarcinoma harboring ROS1-fusion gene was treated with entrectinib. The patient developed lethal arrhythmias three days after drug initiation, including ventricular tachycardia with Brugada-like electrocardiogram changes. Echocardiography and coronary angiography revealed no evidence of acute coronary syndrome or myocarditis. Following the termination of entrectinib, the electrocardiogram abnormality improved within 12 days. Hence, paying special attention to and monitoring electrocardiogram changes is necessary. In addition, it is also necessary to consider early therapeutic interventions and discontinuation of the drug in cases of drug-induced Brugada syndrome.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"299-304"},"PeriodicalIF":0.5,"publicationDate":"2023-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10002091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence. 成功的多学科治疗，atezolizumab加贝伐单抗对一名90岁肝细胞癌复发患者有完全反应。

IF 0.5

International Cancer Conference Journal Pub Date : 2023-06-23 eCollection Date: 2023-10-01 DOI: 10.1007/s13691-023-00618-6

Kiyotaka Hosoda, Takeo Toshima, Junichi Takahashi, Yusuke Yonemura, Yuichi Hisamatsu, Kosuke Hirose, Takaaki Masuda, Yushi Motomura, Tadashi Abe, Yuki Ando, Katsushi Dairaku, Yusuke Nakano, Masahiro Hashimoto, Yoshiki Hiraki, Yuji Soejima, Tomoharu Yoshizumi, Koshi Mimori

{"title":"Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence.","authors":"Kiyotaka Hosoda, Takeo Toshima, Junichi Takahashi, Yusuke Yonemura, Yuichi Hisamatsu, Kosuke Hirose, Takaaki Masuda, Yushi Motomura, Tadashi Abe, Yuki Ando, Katsushi Dairaku, Yusuke Nakano, Masahiro Hashimoto, Yoshiki Hiraki, Yuji Soejima, Tomoharu Yoshizumi, Koshi Mimori","doi":"10.1007/s13691-023-00618-6","DOIUrl":"10.1007/s13691-023-00618-6","url":null,"abstract":"Atezolizumab plus bevacizumab is the first-line regimen in Japan for hepatocellular carcinoma following the results of the IMbrave 150 trial. However, the safety and efficiency of atezolizumab plus bevacizumab in older patients, especially in the oldest-old patients aged over 80 years, have not been thoroughly studied and is still controversial. Eighteen months ago, a 90-year-old woman underwent a laparoscopic hepatectomy (S6) for her primary hepatocellular carcinoma (S6, 2 cm). Nine months after the first surgery, she received transcatheter arterial chemoembolization treatment for solitary hepatocellular carcinoma recurrence (S8, 2 cm). The subsequent recurrence (S3, 1 cm; S5, 2 cm; S8, 1 cm) was uncovered by radiological assessment 1 year after transcatheter arterial chemoembolization treatment. We then initiated chemotherapy treatment with lenvatinib at 8 mg daily. Despite reducing the lenvatinib dosage, the adverse event of severe fatigue and asitia did not resolve; therefore, the regimen of atezolizumab + bevacizumab combination therapy was changed to be started. After the first 2 months, tumor regression was observed on computed tomography; the patient tolerated the atezolizumab + bevacizumab combination regimen over 8 months for 10 cycles without any adverse effects. She finally showed a complete response; no recurrence developed 1 year after the complete response. Therefore, older adult patients may benefit highly from atezolizumab plus bevacizumab with appropriate patient selection.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"12 4","pages":"274-278"},"PeriodicalIF":0.5,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10002507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0